|
Sep 9
|
ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
|
|
Sep 4
|
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
|
|
Aug 8
|
ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
|
Aug 6
|
ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
|
|
Jul 31
|
ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
|
|
Jun 27
|
Dr. Reddy's (RDY) to Acquire Haleon's Nicotine Addiction Drug
|
|
Jun 27
|
Novo Nordisk's (NVO) Hypertension Drug Study Fails to Meet Goal
|
|
Jun 26
|
ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why
|
|
Jun 25
|
Novo Nordisk (NVO) to Invest $4.1B in Clayton Facility Expansion
|
|
Jun 25
|
Alnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals
|
|
Jun 24
|
Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer
|
|
Jun 21
|
JAZZ Falls as Suvecaltamide Tremor Study Fails to Meet Goals
|
|
Jun 19
|
Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals
|
|
Jun 18
|
Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals
|
|
Jun 17
|
Insider Buying: CFO Peter Garcia Acquires Shares of ALX Oncology Holdings Inc (ALXO)
|
|
Jun 14
|
Shattuck (STTK) Announces Positive Interim Data on Cancer Drug
|
|
Jun 11
|
Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study
|
|
Jun 10
|
Geron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up
|
|
Jun 10
|
ChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag
|
|
Jun 10
|
Moderna (MRNA) Submits Updated COVID-19 Jab to FDA for Review
|